Logo-ddj
Submitted: 12 Jun 2021
Revision: 11 Jul 2022
Accepted: 13 Jul 2022
ePublished: 01 Oct 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Dis Diagn. 2022;11(4): 147-151.
doi: 10.34172/ddj.2022.28
  Abstract View: 207
  PDF Download: 180

Original Article

The Comparative Effect of Definitive Chemoradiotherapy and Neoadjuvant Chemoradiotherapy Plus Surgery on One-Year Survival Rate of Esophageal Cancer Patients

Fatemeh Khanaki 1 ORCID logo, Zhaleh Karimi Moghaddam 2* ORCID logo, Hossein Chehre 3 ORCID logo, Koorosh Kamali 4 ORCID logo, Faranak Saghatchi 5 ORCID logo, Hamed Rezaeejam 2,5* ORCID logo

1 Student Research Committee, School of Paramedical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran.
2 Department of Radiation Oncology, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
3 Department of Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
4 Department of Public Health, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran.
5 Department of Radiology, School of Paramedical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran.
*Corresponding Authors: Correspondence to Zhaleh Karimi Moghaddam, Email: , Email: zhkarimi@zums.ac.ir; Correspondence to Hamed Rezaeejam, Email:, Email: hrezaeejam@yahoo.com

Abstract

Background: Esophageal cancer is a malignancy with a poor survival rate, and the optimal management of esophageal cancer patients is still controversial. This study aimed to compare the one-year survival of patients who had received definitive chemoradiotherapy (DCRT) or neoadjuvant chemoradiotherapy plus surgery (NCRT+S).

Materials and Methods: In this cross-sectional descriptive study, the medical records of esophageal cancer were extracted from 2018 to 2019; the last survival status of patients was obtained one year after the end of the treatment course. Data were analyzed using SPSS (version 16), and survival was estimated by the Kaplan-Meier method with the log-rank test. A P value of less than 0.05 was considered significant for all the performed tests.

Results: Among 43 eligible patients, 39.5% were males and 60.5% were females. The mean age of the patients was 68.16±12.03 years. In this population, 81.4% of cases had squamous cell carcinoma (SCC), and the rest had adenocarcinoma (ADC). In addition, 58.1% and 41.9% of cases were treated by DCRT and NCRT+S, respectively. The one-year survival rate was 68% and 66.67% in the DCRT and NCRT+S groups, respectively (P>0.05). The one-year survival rate did not have significant relevance to the age of patients and histologic subtype. In terms of gender, there was no significant difference between males and females regarding the one-year survival rate.

Conclusion: There were no statistically significant differences in the one-year survival rate of the patients in the two treatment groups; thus, further studies are recommended to confirm the results.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 208

Your browser does not support the canvas element.


PDF Download: 180

Your browser does not support the canvas element.